IgM Autoantibodies Can Be Correlated in Cases of Atherosclerosis
By LabMedica International staff writers Posted on 20 Feb 2012 |
Low levels of immunoglobulin-M (IgM) autoantibodies against lipid phosphorylcholine (PC) add prognostic information in acute coronary syndromes (ACS).
The IgM autoantibodies can be easily measured by immunoassay and can be correlated with other known biomarkers in cases of atherosclerosis and other inflammatory diseases.
A team of scientists from the Karolinska Institutet (Stockholm, Sweden), collected and analyzed blood samples from 1,185 patients within 24 hours of admission between September 1995 and March 2001. Serum IgM anti-PC titers were measured by an enzyme-linked immunosorbent assay (ELISA) using a prototype of the Athera CVDefine kit. The assay is based on PCs covalently linked to bovine serum albumin coated onto 96-well microtiter plates. The detection limit was 0.5 U/L and coefficients of variation were less than 7%.
The results of the analysis showed that patients with low levels of anti-PC in connection with ACS and refractory, unstable angina run a greater risk of complications and premature death. The risk of death was more than double in coronary patients with low levels of anti-PC, who also had a significantly higher risk of additional heart attacks or other complications. The results also demonstrated for the first time that low anti-PC titers in ACS are associated with a considerably increased risk of a new acute cardiovascular event during several years, as well as increased mortality risk within, at least, the first 18 months after the primary ACS event. Low anti-PC titers may therefore represent a novel paradigm for reporting reduced atheroprotection in coronary vascular disease (CVD). The Athera CVDefine ELISA kit used in the study is a product of Athera Biotechnologies AB (Stockholm, Sweden).
Johan Frostegård, PhD, lead author and a professor at the Karolinska Institutet said, "The immunological treatment of cardiovascular diseases is clearly a Swedish specialty. Other Swedish researchers maintain that it's apolipoprotein B, an important constituent of LDL, that we should be vaccinating against, but the two aren't mutually exclusive and a combination is conceivable and something that we're now also testing." His team has spent many years developing immunological treatments for atherosclerotic plaque based on exploiting anti-PC to target phosphorylcholine. The study was published online on February 3, 2012, in the International Journal of Cardiology.
Related Links:
Karolinska Institutet
Athera Biotechnologies AB
The IgM autoantibodies can be easily measured by immunoassay and can be correlated with other known biomarkers in cases of atherosclerosis and other inflammatory diseases.
A team of scientists from the Karolinska Institutet (Stockholm, Sweden), collected and analyzed blood samples from 1,185 patients within 24 hours of admission between September 1995 and March 2001. Serum IgM anti-PC titers were measured by an enzyme-linked immunosorbent assay (ELISA) using a prototype of the Athera CVDefine kit. The assay is based on PCs covalently linked to bovine serum albumin coated onto 96-well microtiter plates. The detection limit was 0.5 U/L and coefficients of variation were less than 7%.
The results of the analysis showed that patients with low levels of anti-PC in connection with ACS and refractory, unstable angina run a greater risk of complications and premature death. The risk of death was more than double in coronary patients with low levels of anti-PC, who also had a significantly higher risk of additional heart attacks or other complications. The results also demonstrated for the first time that low anti-PC titers in ACS are associated with a considerably increased risk of a new acute cardiovascular event during several years, as well as increased mortality risk within, at least, the first 18 months after the primary ACS event. Low anti-PC titers may therefore represent a novel paradigm for reporting reduced atheroprotection in coronary vascular disease (CVD). The Athera CVDefine ELISA kit used in the study is a product of Athera Biotechnologies AB (Stockholm, Sweden).
Johan Frostegård, PhD, lead author and a professor at the Karolinska Institutet said, "The immunological treatment of cardiovascular diseases is clearly a Swedish specialty. Other Swedish researchers maintain that it's apolipoprotein B, an important constituent of LDL, that we should be vaccinating against, but the two aren't mutually exclusive and a combination is conceivable and something that we're now also testing." His team has spent many years developing immunological treatments for atherosclerotic plaque based on exploiting anti-PC to target phosphorylcholine. The study was published online on February 3, 2012, in the International Journal of Cardiology.
Related Links:
Karolinska Institutet
Athera Biotechnologies AB
Latest Immunology News
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
- 3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response
- Blood Test for Fungal Infections Could End Invasive Tissue Biopsies
- Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies
- New Discovery in Blood Immune Cells Paves Way for Parkinson's Disease Diagnostic Test
- AI Tool Uses Routine Blood Tests to Predict Immunotherapy Response for Various Cancers
- Blood Test Can Predict How Long Vaccine Immunity Will Last
- Microfluidic Chip-Based Device to Measure Viral Immunity
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune... Read more
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more